The Latest Cardiac and Vascular News
By simplifying complex cardiac anatomy through real-time AI labeling, T-Mode™ Heart removes the training barrier to ultrasound adoption for family physicians and medical students. VANCOUVER, BC, March 23, 2026 /PRNewswire/ — With cardiovascular disease remaining a leading cause of death…
SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that three abstracts featuring Viz HCM, the company’s AI-powered ECG analysis and care coordination solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), part of the Viz Cardio Suite, have been accepted for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March 28–30,
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings. Late-Breaking Oral Presentation:Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CMPresenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of MedicineDate: Monday, March 30 at 2:33 pm CT Posters:Long-Term Benefits With Acoramidis on Serum Transthyretin Concentrations and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Presenter: Sarah Cuddy, M.D., Brigham and Women’s HospitalDate: Saturday, March 28 at 12:30 pm CT Association Between Early Increase in sTTR with Acoramidis and Long-term Effects on Heart Failure – Related Health Status in ATTR-CM: Results from ATTRibute-CM Presenter: Jan Griffin, M.D., Medical University of South CarolinaDate: Saturday, March 28 at 3:30 pm CT Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey Presenter: Jill Waldron, MSN, GNP, MS, University of UtahDate: Monday, March 30 at 9:30 am CT About Attruby™ (acoramidis)INDICATIONAttruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATIONAdverse ReactionsDiarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBioBridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. BridgeBio Media Contact:Bubba Murarka, Executive Vice Presidentcontact@bridgebio.com(650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, Senior Vice President, Strategic Financeir@bridgebio.com
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in AI-based cardiovascular imaging analysis, presented findings from its multicenter INVICTUS registry at the recent European Congress of Radiology (ECR 2026) in Vienna, Austria. The presentation titled, “Artificial Intelligence-Based CCTA Quantification of Atherosclerosis Burden: Comparison With IVUS in the INVICTUS Registry” was presented by Rine Nakanishi, MD, PhD, during the Clinical Trials in Radiology: Spotlight Session on March 5, 2026. The anal
Findings come as ACC/AHA guidelines recognize polygenic risk as an ASCVD risk enhancer MENLO PARK, Calif., March 20, 2026 /PRNewswire/ — MyOme, a leader in clinical whole-genome analysis and integrated risk modeling, today announced research showing that integrating polygenic scores with…
MENLO PARK, Calif., March 19, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”) today announced that two abstracts related to the ENGULF study and the Hēlo® Platform have been accepted as late-breaking podium presentations at the Society of Interventional Radiology (SIR) Annual…
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company’s proprietary Ultra-Low Temperature Ablation (ULTA) technology under Expanded Access authorization from the U.S. Food and Drug Administration (FDA). The procedures addr
HOUSTON & PANAMA CITY, Panama–(BUSINESS WIRE)–XCath announced successful completion of world’s first telerobotic mechanical thrombectomy for stroke using the XCath Iris Surgical Robotic System.
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to d
